Member Info for crumbs

Be taking up my OO's doubt this will have too bad an impact on current sp though probably a red day just cuz it's AIM

Platform arrives too :)

That's the SCIB1 elephant dealt with...not in the way I'd have hoped for but still IP intact and more value going to be added

Seems they were right...

Cash rich and out looking to do deals...also they are already teamed up with Ichor so who knows but seems this year could be a very busy one for deals in the bio industry... almost like scancells timing is becoming perfect. Share buybacks have been the name of the game for a few years now as M&A went through a quiet patch, but with deals ramping up in 2018, J&J says its boosting its R&D budget over the coming years. Will the Big Pharma be looking to beef up its pipeline? Celgene, Gilead, Sanofi and Novartis have all made some big deals in recent months, spending tens of billions on marketed and pipeline drugs in bleeding disorders, cutting-edge cancer therapies and rare diseases. With the new tax cuts coming out of the Trump administration lowering corporate rates for U.S. biopharmas, some have opted for share buybacks, which rankles with those pushing for innovation. But others have been looking to use the cash for R&D play. https://www.fiercebiotech.com/biotech/j-j-says-it-has-15-more-to-splash-r-d-thanks-to-tax-cuts-so-will-we-see-more-pipeline-plays

To have multi products of 2 possibly soon 3 platforms multi trials ahead one beyond the norm successful trial on one product already in the bag in a none gameable condition OS data amazing... Great to be going forwards with some big names in the field and probably soon with their non dilutive risk negating financial backing...I think it really is all about the science and then having the right team and strategy to take that science from lab to clinic to market...Go team scancell

Retweeting Genentech tweets again... no idea what it must mean hopefully hootwings can explain :)

Great news mate :) I really hope all your other conditions improve there must be some punch on the C7 immune system.

Read: Merck says it has scrapped work in other diseases to put resources into Keytruda, marking a big cultural change for the company, according to people who have worked there. "I said to everyone, 'Whatever other projects you're working on, you can stop now, because we're going to be doing this, and we're going to put a lot of muscle behind this,'" Dr. Perlmutter said. He said he based the decision on early clinical data showing that Keytruda shrank some tumors effectively, and on the knowledge that rival Bristol-Myers Squibb Co. had already released positive study results of its rival drug, Opdivo. https://www.marketwatch.com/story/why-merck-is-betting-on-one-big-cancer-drug-2018-04-16 Merck up 2.2% not sure what amounts to in it's mcap increase but I imagine more than �50 million :)

A bad day a nice bit of blue and plenty going on at AACR with some nice RG retweets...For anyone interested Genentech's latest podcast is once again about immunotherapy: https://www.gene.com/stories/two-scientists-walk-into-a-bar Wishing C7 all the best with his results.

Progress reported as being made including on pension.... sounds promising

Yeah.. let's hope something comes of it.

Day of mediated talks between RM and CWU today... and Moya has turned up!

Announced -19th October.

http://en.ria.ru/russia/20140305/188113312/Russia-Mulls-Seizing-Foreign-Assets-Over-Sanctions-Threat.html

Is a great share to be in!! if you play it right you can make on the divis and the rises

3 koshek wells in production by mid march

All the time:)